Operations

Accenture Launches the Intelligent Patient Service Exchange to Help Life Sciences Companies Integrate Technology Solutions into Their Patient Services Programs

February 21, 2017

NEW YORK–(BUSINESS WIRE)–Accenture (NYSE:ACN) has launched the Intelligent Patient Service Exchange, a digital marketplace of third-party technology solutions available to life sciences companies to enhance patient support and improve the overall patient treatment experience. “With the launch of the Intelligent Patient Service Exchange, our platform continues to be instrumental in helping life sciences companies use […]

Baxter Declares Quarterly Dividend

February 21, 2017

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX) today announced a quarterly dividend. The Board of Directors of Baxter has declared a quarterly cash dividend of $0.13 per common share, payable on April 3, 2017 to shareholders of record as of March 3, 2017. The indicated annual dividend rate is $0.52 per share. Baxter provides a broad […]

First Comprehensive Pediatric Hematology-Oncology Initiative Launched in Africa

February 21, 2017

NEW YORK, HOUSTON, & GABORONE, Botswana–(BUSINESS WIRE)–His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama of the Republic of Botswana, the Honorable Minister Dorcas Makgato of the Ministry of Health and Wellness, the Bristol-Myers Squibb Foundation, Texas Children’s Cancer and Hematology Centers (TXCH) and Baylor College of Medicine International Pediatric AIDS Initiative at […]

SAPHEX 2017

February 21, 2017

Edge Therapeutics Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)

February 21, 2017

BERKELEY HEIGHTS, N.J., Feb. 21, 2017 (GLOBE NEWSWIRE) — Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced the appointment of Alyssa Wyant as Senior Vice President, Regulatory Affairs. Ms. Wyant will oversee all facets of Edge’s regulatory activities, providing oversight for all […]

Neovacs and BioSense Sign Option Agreement Worth Up to €65 Million Plus Royalties for Chinese Development and Commercial Rights to IFNα Kinoid for Lupus and Dermatomyositis

February 21, 2017

PARIS, Feb. 21, 2017 (GLOBE NEWSWIRE) — Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has signed with BioSense Global LLC a commercial license option agreement for its IFNα Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront […]

Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28

February 21, 2017

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) — Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and year ended December 31, 2016, and provide a general business overview on Tuesday, February 28, 2017, at 4:30 p.m. ET […]

Endocyte Appoints Michael T. Andriole as Chief Financial Officer

February 21, 2017

WEST LAFAYETTE, Ind., Feb. 21, 2017 (GLOBE NEWSWIRE) — Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Michael T. Andriole has been appointed as chief financial officer. Mr. Andriole has more than 20 years of experience in a range of […]

Vernalis PLC: Unaudited Interim Results for the six months ended 31 December 2016

February 21, 2017

WINNERSH, UNITED KINGDOM–(Marketwired – Feb 21, 2017) – Vernalis PLC (LSE: VER) LSE: VER 21 February 2017 Vernalis plc Unaudited Interim Results for the six months ended 31 December 2016 Tuzistra® XR prescriptions growing steadily as 2016/2017 US cough cold season progresses Two further NDAs from cough cold franchise accepted for review by FDA with […]

Arch Biopartners Announces Non-Brokered Private Placement Financing

February 21, 2017

TORONTO, ONTARIO–(Marketwired – Feb. 21, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 1,000,000 common shares priced at $0.40 per common share (the “Common Shares”) for gross proceeds of up to $400,000 (the “Offering”). All Common […]

RDD Pharma Announces Patents Granted in Israel and EU

February 21, 2017

NEW YORK, Feb. 21, 2017 /PRNewswire/ — RDD Pharma, a leader in developing treatments for anorectal disorders, announces the patent covering methods for treating fecal incontinence has been granted in Israel. The patent is based on the increase in resting anal pressure via a topical administration of RDD-0315, an alpha-agonist. Patents have already been granted […]

AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook

February 21, 2017

ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ — AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2016 and provided an outlook for 2017.   Highlights:   Fourth quarter total revenue of $191.3 million, up 51% from 2015 Full year total revenue of $570.5 million, up […]

AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products

February 21, 2017

ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ — AMRI (NASDAQ: AMRI) today announced that it has entered into an agreement with the pharmaceutical group Ferrer and Accord Healthcare, Inc. (“Accord Healthcare”) to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the United States with the option to partner […]

Momentum Announces Media Partnership with PharmaVOICE on Momentum’s IP Counsel Exchange

February 21, 2017

New York, NY – Momentum Events announces that PharmaVOICE has joined the IP Counsel Exchange in San Jose as an official event partner. The IP Counsel Exchange (ptabevents.com) is the premier tactical event and benchmarking event for corporate IP counsel and in-house executives with a specific focus on IP, patent portfolio management and IP litigation […]

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 20, 2017

LEXINGTON, MA–(Marketwired – Feb 17, 2017) – Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,555,555 shares of its common stock, including 333,333 shares sold in connection with the […]

DBV Technologies Reports December 31, 2016 Cash Position

February 20, 2017

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), today announced its cash and cash equivalents as of December 31, 2016. Full year 2016 financial results will be announced on March 15, 2017. Cash and cash equivalents DBV’s cash and cash equivalents amounted to €256.5 million as of December 31, 2016, compared […]

AssistRx and Surescripts Collaborate to Eliminate Manual Processes for Specialty Medications

February 20, 2017

ORLANDO, FL–(Marketwired – Feb 20, 2017) – AssistRx (ARx), the leading enterprise technology platform focused on specialty and highly-managed medications, announces today the integration of ARx’s iAssist Workflows into Surescripts Electronic Prescribing, addressing the specialty Rx workflow to eliminate the inefficient manual processes that strain pharmacies and providers daily. Surescripts is the single most trusted […]

Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences

February 17, 2017

PALO ALTO, Calif., Feb 16, 2017 /PRNewswire/ — Amygdala Neurosciences Inc., a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders, has entered into an agreement with Gilead Sciences, Inc. for the acquisition of GS-6637, a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions […]

Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US

February 17, 2017

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 16, 2017 /PRNewswire-USNewswire/ — Medinol, a global interventional cardiology device company, today announced the appointment of Harvey J. Berger, M.D., founder and past Chairman and Chief Executive Officer of ARIAD Pharmaceuticals, Inc., to the newly created position of Executive Chairman of Medinol US Inc., effective immediately. Dr. Berger, […]

AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer

February 17, 2017

REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Vincent J. Angotti has been appointed chief executive officer and a member of the company’s board of directors, effective Monday, […]

Thyrve Microbiome Raises Seed Round From PivotNorth and Plug & Play Ventures to Improve Wellness Through Your Stomach

February 17, 2017

SAN FRANCISCO, Feb. 17, 2017 /PRNewswire/ — Thryve, providers of high quality microbiotics and microbiome testing, today announced it has closed a seed round of financing from PivotNorth Ventures and Plug & Play Ventures. Thryve recently launched the first at home microbiome testing kit and probiotics subscription service on the market to wide appeal. Thryve’s […]

ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016

February 17, 2017

WALTHAM, Mass.–(BUSINESS WIRE)– ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the six-month period and quarter ended December 31, 2016. “In 2016, we strengthened ImmunoGen operationally and financially with a focused strategy and disciplined execution,” […]

CEL-SCI Announces $1.0 Million Registered Direct Offering

February 17, 2017

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $1.0 million in a registered direct offering. The closing of the offering is expected to take place on or about February 23, 2017, subject […]

FEEDBACK